- Home
- IMMR vs OTLK Comparison
IMMR vs OTLK Comparison
Compare IMMR & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMMR | OTLK |
|---|---|---|
| Founded | 1993 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 215.8M | 249.6M |
| IPO Year | 1999 | 2016 |
Fundamental Metrics
Financial Performance| Metric | IMMR | OTLK |
|---|---|---|
| Price | $7.57 | $1.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $13.50 | $2.50 |
| AVG Volume (30 Days) | 513.2K | ★ 10.2M |
| Earning Date | 04-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.11% | N/A |
| EPS Growth | N/A | ★ 55.91 |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $35,013,000.00 | $8,146,123.00 |
| Revenue This Year | N/A | $1,430.98 |
| Revenue Next Year | N/A | $173.23 |
| P/E Ratio | $326.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $0.16 |
| 52 Week High | $7.50 | $3.39 |
Technical Indicators
Market Signals| Indicator | IMMR | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 68.37 | 39.54 |
| Support Level | $6.31 | $0.26 |
| Resistance Level | N/A | $1.95 |
| Average True Range (ATR) | 0.29 | 0.21 |
| MACD | 0.04 | -0.07 |
| Stochastic Oscillator | 85.61 | 5.42 |
Price Performance
Historical ComparisonAbout IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.